Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors are a Class IA recommendation in the guideline-directed medical therapy HFrEF (heart failure with reduced ejection fraction) and Class IIA recommendation in HFpEF (heart failure with preserved ejection fraction) for reductions in heart failure hospitalization and CV mortality [116]. This evidence concerns the gene SLC5A2 and heart failure.